FDC fianlimab+cemiplimab (NCT06769698)

Name: FDC fianlimab+cemiplimab trial for Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT06769698)
Uploaded: 2026-10-31T06:22:21.323Z
Duration: 1 min 31 s
Description: FDC fianlimab+cemiplimab trial for Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT06769698). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06769698.

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: a one-minute explainerNCT067696981 min

FDC fianlimab+cemiplimab trial for Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT06769698). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with recurrent or metastatic squamous cancer of the mouth, oropharynx, larynx or hypopharynx unsuitable for curative local treatment. PD-L1 CPS must be at least one; prior systemic treatment for recurrent/metastatic disease is excluded.

The idea: block two immune brakes, LAG-3 and PD-1. Within HPV-defined groups, patients receive fianlimab plus cemiplimab or cemiplimab plus placebo. Researchers compare tumor response and side effects.

This phase 2 study plans 120 patients. Regeneron sponsors it, with 18 recruiting US sites. Early progression after curative-intent systemic treatment is excluded.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.